TY  - JOUR

T1  - Cost-effectiveness of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab in patients with a history of myocardial infarction in Sweden

JO  - European Heart Journal - Quality of Care and Clinical Outcomes

PY  - 2020/10/16

AU  - Landmesser U

AU  - Lindgren P

AU  - Hagström E

AU  - van Hout B

AU  - Villa G

AU  - Pemberton-Ross P

AU  - Arellano J

AU  - Svensson ME

AU  - Sibartie M

AU  - Fonarow GC

ED  - 

DO  - DOI: 10.1093/ehjqcco/qcaa072

PB  - Oxford University Press (OUP)

VL  - 8

IS  - 1

SP  - 31

EP  - 38

Y2  - 2024/12/22

ER  -